Equities analysts forecast that Nightstar Therapeutics PLC (NASDAQ:NITE) will post earnings of ($0.36) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Nightstar Therapeutics’ earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.36). Nightstar Therapeutics reported earnings per share of ($0.52) during the same quarter last year, which would suggest a positive year-over-year growth rate of 30.8%. The business is scheduled to announce its next earnings report on Wednesday, June 5th.
On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.56) per share for the current year, with EPS estimates ranging from ($1.93) to ($1.41). For the next year, analysts expect that the company will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.52) to ($1.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Nightstar Therapeutics.
A number of research analysts have issued reports on NITE shares. Chardan Capital restated a “buy” rating on shares of Nightstar Therapeutics in a research report on Monday, March 4th. Cantor Fitzgerald restated a “buy” rating and set a $42.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, February 26th. ValuEngine upgraded shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research upgraded shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, January 9th. Finally, UBS Group started coverage on shares of Nightstar Therapeutics in a research report on Friday, January 4th. They set a “buy” rating and a $21.00 target price on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $27.06.
In related news, insider Tuyen Ong sold 2,446 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $25.31, for a total transaction of $61,908.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO David A. Fellows sold 9,305 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $25.31, for a total transaction of $235,509.55. The disclosure for this sale can be found here. Insiders have sold a total of 12,142 shares of company stock worth $307,314 in the last quarter.
A number of large investors have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its stake in Nightstar Therapeutics by 106.7% in the 4th quarter. Squarepoint Ops LLC now owns 43,886 shares of the company’s stock valued at $506,000 after purchasing an additional 22,651 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in Nightstar Therapeutics in the 4th quarter valued at approximately $127,000. Virtus ETF Advisers LLC bought a new position in shares of Nightstar Therapeutics during the fourth quarter valued at $314,000. Marshall Wace LLP bought a new position in shares of Nightstar Therapeutics during the third quarter valued at $1,205,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Nightstar Therapeutics during the third quarter valued at $31,201,000. 39.15% of the stock is owned by institutional investors and hedge funds.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Further Reading: What are gap-up stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.